HC Wainwright Lifts Earnings Estimates for Microbot Medical

Microbot Medical Inc. (NASDAQ:MBOT) – Equities researchers at HC Wainwright upped their Q1 2025 earnings per share (EPS) estimates for shares of Microbot Medical in a report released on Thursday, April 10th. HC Wainwright analyst R. Selvaraju now expects that the biotechnology company will earn ($0.13) per share for the quarter, up from their prior estimate of ($0.15). HC Wainwright has a “Buy” rating and a $9.00 price target on the stock. The consensus estimate for Microbot Medical’s current full-year earnings is ($0.71) per share. HC Wainwright also issued estimates for Microbot Medical’s Q2 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.09) EPS, Q4 2025 earnings at ($0.07) EPS and FY2025 earnings at ($0.40) EPS.

Microbot Medical (NASDAQ:MBOT) last issued its quarterly earnings data on Wednesday, March 26th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.02).

Microbot Medical Trading Up 11.8 %

MBOT stock opened at $2.55 on Monday. The stock has a 50-day moving average price of $1.68 and a two-hundred day moving average price of $1.39. Microbot Medical has a 1 year low of $0.82 and a 1 year high of $3.38. The stock has a market cap of $88.60 million, a PE ratio of -3.19 and a beta of 1.40.

Institutional Investors Weigh In On Microbot Medical

An institutional investor recently raised its position in Microbot Medical stock. Geode Capital Management LLC raised its holdings in shares of Microbot Medical Inc. (NASDAQ:MBOT) by 7.9% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 142,659 shares of the biotechnology company’s stock after acquiring an additional 10,442 shares during the quarter. Geode Capital Management LLC owned approximately 0.70% of Microbot Medical worth $160,000 at the end of the most recent reporting period. 16.30% of the stock is owned by hedge funds and other institutional investors.

About Microbot Medical

Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.